Learn how you and your patients can have it both ways.
Choice is great and a vital part of your aesthetics practice but sometimes a little clarity can help us make the most of the choices available to us.
Since March this year we were able to choose between ready-to-use and powder neuromodulators, Alluzience (Botulinum toxin type-A) and Azzalure (Botulinum toxin type-A).
To help clinics make the most of this new choice, both Galderma and Aesthetics Journal are running an online webinar – Innovation Through Science: The Clinical Evidence of Galderma’s Neuromodulator Portfolio on, 25th April at 7:30pm
Well-known presenters, Dr Munir Somji and Dr Lara Watson will use the one-hour presentation to explain how to make the most of these two neuromodulators.
Dr Lara Watson is excited at the possibilities that this choice offers:
“This new era in neuromodulation is revolutionising not only the patient experience but also that of the practitioner. It’s an exciting time for aesthetic medicine and pertinent, now more than ever, to remain informed and up to date if we are to continue to deliver the very best outcomes to our patients.”
The presentation will be followed by a questions and answers session to help clarify your individual questions.
If you wish to participate, book your place by clicking on the link below.
This is a promotional webinar by Galderma for Healthcare Professionals Only.
Register now by clicking here.
Please click here for Alluzience (Botulinum toxin type A) Prescribing information for the UK.
Please click here for Azzalure (Botulinum toxin type A) Prescribing information for the UK.
Adverse events should be reported. United Kingdom: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Galderma (UK) Ltd: E-mail: [email protected] Tel: +44 (0)300 3035674
UKI-ALZ-2300051 DOP April 2023
